Abstract：【Objective】To investigate the mechanism of long non-coding RNA insulin-like growth factor 2 antisense transcript (lncRNA IGF2-AS) in the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). 【Methods】 Fifty 6-month-old SD female rats were selected as the research objects and divided into 5 groups with 10 rats in each group by random number table method. Group A was sham operation group, group B, group C and group D underwent surgical resection of both ovaries to construct the ovariectomized (OVX) rat model (the success rate of each group was 100%), and the remaining 10 were control group after successful construction. After the OVX rat model was successfully constructed, the rats in group C were given lncRNA IGF2-AS simulants, the rats in group D were given lncRNA IGF2-AS inhibitors, and the other groups were given equal volume normal saline. The rats in all groups were routinely fed for 8 weeks. Bone mineral density, body weight, blood urea nitrogen level, femur biomechanical strength, serum index level, lncRNA IGF2-AS, miR-3126-5p and KLK4 expression levels, and BMSCs osteogenic differentiation level were compared in all groups after feeding for 8 weeks. 【Results】 There was no significant difference in body weight among all groups (P>0.05). The bone mineral density of L5 and femur of rats in groups B and D were lower than those in group A and the control group, the bone mineral density of L5 and femur of rats in group C was higher than that in group A and the control group, and the bone mineral density of L5 and femur of rats in group B was higher than that in group D, with statistical significance (P<0.05). The blood urea nitrogen levels of rats in group B, C and D were higher than those in group A and the control group, the blood urea nitrogen level of rats in group C was lower than that in group B and D, and the blood urea nitrogen level of rats in group B was lower than that in group D, all difference were statistical significance (P<0.05). The maximum femur load and Young's modulus of rats in group B, C and D were lower than those in group A and the control group, and the maximum femur load and Young's modulus of rats in group C were higher than those in group B and D, and those in group B were higher than those in group D, with all statistical significance (P<0.05). Serum Ca and P levels of rats in group B, C and D were lower than those in group A and the control group, while serum ALP, PⅠNP and CTX-Ⅰ levels were higher than those in group A and control group, the difference were significant (P<0.05). The serum Ca and P levels of rats in group C were higher than those in group B and D, and levels of Ca and P in group B was higher than those in group D; While serum ALP, PⅠNP and CTX-Ⅰ levels of rats in group C were lower than those in group B and D, and those in group B were lower than those in group D. All differences were statistically significant (P<0.05). There was no significant difference in the expression levels of lncRNA IGF2-AS, miR-3126-5p and KLK4 in group A, group B and the control group (P>0.05). The expression levels of lncRNA IGF2-AS, miR-3126-5p and KLK4 in group C were higher than those in groups A, B, D and control group, and the differences were statistically significant (P<0.05). There was no statistically significant difference in the distribution of BMSCs osteoblasts between group A and control group. The distribution of BMSCs osteoblasts in groups B, C and D was less than that in groups A and control group, and the distribution of BMSCs osteoblasts in group C was more than that in groups B and D, and group B has more distribution of BMSCs osteoblasts than that in group D. 【Conclusion】 Overexpression of lncRNA IGF2-AS can promote osteogenic differentiation of BMSCs by regulating miR-3126-5p/KLK4 signaling pathway, improve bone mineral density, blood urea nitrogen levels and serum levels of Ca, P, ALP, PⅠNP and CTX-Ⅰ, and enhance the biomechanical strength of femur.
[1] ARSHAD M, JALIL F, JALEEL H, et al. Bone marrow derived mesenchymal stem cells therapy for rheumatoid arthritis - a concise review of past ten years[J].Mol Biol Rep,2023,50(5):4619-4629.
[2] KALOU Y, AL-KHANI A M, HAIDER K H. Bone marrow mesenchymal stem cells for heart failure treatment: a systematic review and meta-analysis[J].Heart Lung Circ,2023,32(7):870-880.
[3] 姚顺春,张永川. lncRNA FEZF1-AS1和IGF2BP1在肝癌组织中的表达及临床意义[J].蚌埠医学院学报,2023,48(10):1346-1350.
[4] 钟晓鸣,刘洪洋,张蕾,等. lncRNA IGF2-AS调控IGF2对骨髓间充质干细胞心肌样分化的影响[J].天津医药,2022,50(4):350-356.
[5] JIN X Y, FENG J J, CHENG X. LncRNA IGF2-AS promotes endometriosis progression through targeting miR-370-3p/IGF2 axis and activating PI3K/AKT/mTOR signaling pathway[J].J Assist Reprod Genet,2022,39(12):2699-2710.
[6] 丁乙轩,王宇婷,梅文通,等. 人脐带间充质干细胞来源的外泌体通过miRNAs促进胰腺癌细胞生长[J].中华肿瘤杂志,2023,45(1):50-55.
[7] DELLA BELLA E, MENZEL U, BASOLI V, et al. Differential regulation of circRNA, miRNA, and piRNA during early osteogenic and chondrogenic differentiation of human mesenchymal stromal cells[J].Cells,2020,9(2):398.
[8] XIANG Y, ZONG Q B, LIU H, et al. lncRNA IGF2-AS regulates miR-500a-3p/PPP4R1/p-VEGFR2 signalling pathway to promote thyroid carcinoma progression and tubulogenesis[J].Clin Transl Med,2023,13(4):e1240.
[9] 王星,胡亚红. 急性心肌梗死患者血清lncRNA MALAT1水平与心肌损伤标志物、凝血功能指标的相关性研究[J].医学临床研究,2022,39(4):553-556.
[10] 付永良,郝耀,赵巍,等. 长链非编码RNA胰岛素样生长因子2-AS对大鼠骨质疏松性骨折的影响及其机制[J].中华实验外科杂志,2024,41(5):1029-1032.
[11] LIU F, LIANG Y B, LIN X Y. MiR-151b inhibits osteoblast differentiation via downregulating Msx2[J].Connect Tissue Res,2022,63(2):112-123.
[12] LI T W, ZHANG Y, ZHOU Z, et al. Phosphodiesterase type 5 inhibitor tadalafil reduces prostatic fibrosis via MiR-3126-3p/FGF9 axis in benign prostatic hyperplasia[J].Biol Direct,2024,19(1):61.
[13] TSE B W, KRYZA T, YEH M C, et al. KLK4 induces anti-tumor effects in human xenograft mouse models of orthotopic and metastatic prostate cancer[J].Cancers (Basel),2020,12(12):3501.
[14] CHENG H L, WANG N, TIAN J, et al. Circular RNA Circ_0025033 promotes the evolvement of ovarian cancer through the regulation of miR-330-5p/KLK4 axis[J].Cancer Manag Res,2020,12(23):2753-2765.
2024, Vol. 41 
